Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
58 hedge funds and large institutions have $119M invested in Cidara Therapeutics in 2016 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 6 reducing their positions, and 5 closing their positions.
333% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 6
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
31% more capital invested
Capital invested by funds: $90.2M → $119M (+$28.3M)
14% more funds holding
Funds holding: 51 → 58 (+7)
3.42% more ownership
Funds ownership: 0% → 3.42% (+3.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$5.14M |
| 2 |
BC
Broadfin Capital
New York
|
+$4.11M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$3.09M |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.66M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.53M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$240K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$229K |
| 3 |
SIM
Spark Investment Management
New York
|
-$172K |
| 4 |
TG
TLP Group
Evanston,
Illinois
|
-$62K |
| 5 |
RhumbLine Advisers
Boston,
Massachusetts
|
-$33.7K |
CDTX Hedge Fund Activity: Q4 2016 in Review
58 of the 4,007 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2016, worth a combined $119M — up 31% from $90.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CDTX positions and 5 closed out — a net gain of 8 holders — while 26 added to existing stakes and 6 trimmed.
The largest buyer was Omega Fund Management, opening a new position worth an estimated $5.14M. The largest seller was Putnam Investments, cutting an estimated $240K.
- 58 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2016, up from 51 in Q3 2016.
- Funds reported $119M of Cidara Therapeutics stock for Q4 2016, up 31% quarter-over-quarter.
- 13 funds opened new Cidara Therapeutics positions in Q4 2016 and 5 closed out, a net change of +8 holders.
- The largest Cidara Therapeutics buyer in Q4 2016 was Omega Fund Management, an estimated $5.14M added.
- The largest Cidara Therapeutics seller in Q4 2016 was Putnam Investments, an estimated $240K sold.
Based on aggregated 13F filings for Q4 2016.